vhivus tech page mastheadbackground image

VH IVUS imaging:
Real-time lesion assessment in the cath lab


Contact information

* This field is mandatory
By specifying your reason for contact we will be able to provide you with a better service.
We work with partners and distributors who may contact you about this Philips product on our behalf.

Final CEE consent

VH IVUS imaging provides a colorized tissue map of plaque composition with automated lumen and vessel measurements.* 

VH IVUS technology uses advanced, proprietary spectral analysis techniques to classify plaque into four tissue types with 93-97% accuracy.1

Complete lesion assessment

VH IVUS provides a colorized tissue map of plaque composition for complete lesion assessment. Based on more than 15 years of research and 350 scientific publications, including the landmark PROSPECT trial, VH IVUS can assist you with lesion risk assessment, identification of necrotic core for optimizing stent placement, and monitoring of transplant patients for cardiac allograft vasculopathy.
VhIvus LesionAssessment

VH IVUS features

Colorized tissue map

VhIvus colorizedTissue
For complete lesion assessment, VH IVUS provides a colorized tissue map of four tissue types:
  • Necrotic core
  • Dense calcium
  • Fibrous
  • Fibro-fatty

Necrotic core/dense calcium only mode

VhIvus lumen vessel measurement
For a simplified view, VH IVUS features an alternate option to display only necrotic core and dense calcium.

Automatic border contours

VhIvus auto borders
VH IVUS provides automatic border contours for full segment analysis.

Clinical applications for VH IVUS2

VhIvus clinical applications

Lesion risk and assessment of disease severity2

VH IVUS may help assess lesion risk:

  • VH IVUS may help change the risk profile of non-culprit, angiographically intermediate lesions.
  • VH IVUS may improve the accuracy of IVUS-based assessments of lesion significance and help guide strategies for therapy and follow-up.

Longitudinal stent placement

Landing stent edges in necrotic core increases the risk of stent thrombosis.3 With VH IVUS, the location of necrotic core can be identified and stent placement optimized.
Grayscale IVUS vs VH IVUS

Grayscale IVUS vs VH IVUS

In acute myocardial infarction patients, the plaque ruptures that cause clinical events are often located proximal to the angiographic narrowing, with geographic miss resulting 60% of the time.4,5 Grayscale IVUS can identify the rupture site, and in addition VH IVUS can show how far the associated necrotic core extends.

Transplant patient monitoring


VH IVUS findings of inflammatory plaque support early diagnosis of cardiac allograft vasculopathy.Results may help guide optimization of the patient’s immunotherapy regimen and follow-up strategy.

Culprit of the culprit animation

Culprit of the Culprit Animation

Related products

    Core Precision guided therapy system


    • Choice of FFR, iFR, and IVUS modalities on a single integrated platform
    • Delivers convenience in your workflow with true integration
    • Always on and ready for use when you need it
    Core Mobile Precision guided therapy system

    Core Mobile  

    • Choice of FFR, iFR, and IVUS modalities on a single mobile platform
    • Delivers convenience by offering flexibility to service multiple rooms
    • Offers an intuitive interface for optimal ease of use

1 Nair A, Margolis M, Kuban B, Vince D. Automated Coronary Plaque Characterisation with Intravascular Ultrasound Backscatter: Ex Vivo Validation. EuroIntervention. 2007; 3: 

2 Stone et al. A prospective natural history study of altherosclerosis . N Engl J Med 2011;364:226-35

3 König A, Margolis MP, Virmani, R, Holmes D, Klauss V. Technology insight: in vivo coronary plaque classification by intravascular ultrasonography radiofrequency analysis. Nat Clin Pract Cardiovasc Med. 2008;5(4):219‐229.

4 As presented by Dariusz Dudek, Snowmass 2009.

5 Legutko J, Jakala J, Mintz GS, et al. Radiofrequencyaintravascular ultrasound assessment of lesion coverage after angiography‐guided emergent percutaneous coronary intervention in patients with non‐ST elevation myocardial infarction. Am J Cardiol. 2013;112(12):1854-1859.

6 Raichlin et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol. 2009;53:1279-1286.


*Safety and effectiveness of VH IVUS for use in the characterization of vascular lesions and tissue types has not been established

You are about to visit a Philips global content page

You are about to visit the Philips USA website.

You are about to visit a Philips global content page

You are about to visit the Philips USA website.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.